FDA Approved Indications for this Orphan Drug:

The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy.

FDA Marketing Approval issued as of:
05/07/2001

Orphan Drug exclusivity ends on:
05/07/2008
Company Making and Marketing this drug:
Genzyme Corporation

FDA Designation Date:
10/20/97

FDA Drug Designation:
Treatment of chronic lymphocytic leukemia.